PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

• Published in: Acta pharmacologica Sinica Vol. 34; no. 2; pp. 255 - 261
• Main Authors: Pei, Qi, Huang, Qiong, Yang, Guo-ping, Zhao, Ying-chun, Yin, Ji-ye, Song, Min, Zheng, Yi, Mo, Zhao-hui, Zhou, Hong-hao, Liu, Zhao-qian
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2013; Nature Publishing Group
• Subjects: Aged; Biomedical and Life Sciences; Biomedicine; Blood Glucose - analysis; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - genetics; Female; Genotype; Humans; Hypoglycemic Agents - therapeutic use; Immunology; Internal Medicine; Male; Medical Microbiology; Middle Aged; Original; original-article; Pharmacology/Toxicology; Polymorphism, Single Nucleotide; PPAR gamma - genetics; Receptor-Like Protein Tyrosine Phosphatases, Class 2 - genetics; Thiazolidinediones - therapeutic use; Vaccine; PPAR-γ2 rs1801282; pioglitazone; type 2 diabetes; genetic polymorphisms; PTPRD rs17584499; Chinese Han population
• ISSN: 1671-4083; 1745-7254; 1745-7254
• DOI: 10.1038/aps.2012.144

Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po ) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268–0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135–3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.